North Carolina's Sprout Pharmaceuticals put together a $15 million funding round, cash the biotech will use to make another go at FDA approval for its female sexual dysfunction treatment. As the Triangle Business Journal reports, Sprout's latest financing will help pay for the three new Phase I studies the agency requested after rejecting its drug late last year. The pill, flibanserin, is designed to treat hypoactive sexual desire disorder, and Sprout has said it plans to resubmit the drug this quarter. Story